Janice Smith

760 total citations
37 papers, 298 citations indexed

About

Janice Smith is a scholar working on Physiology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Janice Smith has authored 37 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 11 papers in Psychiatry and Mental health and 7 papers in Cognitive Neuroscience. Recurrent topics in Janice Smith's work include Alzheimer's disease research and treatments (11 papers), Autism Spectrum Disorder Research (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Janice Smith is often cited by papers focused on Alzheimer's disease research and treatments (11 papers), Autism Spectrum Disorder Research (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Janice Smith collaborates with scholars based in United Kingdom, Switzerland and United States. Janice Smith's co-authors include Paulo Fontoura, M. Oliver, G. Conole, Stephen W. White, Rachelle S. Doody, Stephen Salloway, Gregory Klein, Kaj Blennow, Merçé Boada and Sandra E. Black and has published in prestigious journals such as Neurology, American Journal of Obstetrics and Gynecology and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Janice Smith

33 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janice Smith United Kingdom 10 86 54 44 44 39 37 298
Zorana Pavlović Serbia 10 22 0.3× 70 1.3× 45 1.0× 19 0.4× 18 0.5× 20 371
Martin Víta United States 10 119 1.4× 51 0.9× 130 3.0× 28 0.6× 10 0.3× 29 374
Nicole Batsch United States 4 64 0.7× 155 2.9× 36 0.8× 28 0.6× 5 0.1× 5 420
Louise Taylor United Kingdom 10 111 1.3× 40 0.7× 243 5.5× 39 0.9× 11 0.3× 24 523
Konstantinos Bonotis Greece 10 111 1.3× 95 1.8× 20 0.5× 13 0.3× 18 0.5× 30 554
Chieh-Liang Huang Taiwan 8 31 0.4× 44 0.8× 86 2.0× 25 0.6× 15 0.4× 14 523
Kevin Butler United Kingdom 12 64 0.7× 37 0.7× 36 0.8× 32 0.7× 36 0.9× 38 482
Zeeshan Mansuri United States 14 33 0.4× 153 2.8× 69 1.6× 50 1.1× 6 0.2× 80 492
Morgan Green United States 6 107 1.2× 23 0.4× 31 0.7× 26 0.6× 8 0.2× 16 485
Susan Worley United States 5 64 0.7× 27 0.5× 23 0.5× 51 1.2× 5 0.1× 11 204

Countries citing papers authored by Janice Smith

Since Specialization
Citations

This map shows the geographic impact of Janice Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice Smith more than expected).

Fields of papers citing papers by Janice Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice Smith. The network helps show where Janice Smith may publish in the future.

Co-authorship network of co-authors of Janice Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Janice Smith. A scholar is included among the top collaborators of Janice Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice Smith. Janice Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boada, Merçé, Szofia Bullain, Tobias Bittner, et al.. (2024). Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). Journal of Alzheimer s Disease. 103(2). 528–541.
2.
Salloway, Stephen, Nicola Voyle, Christopher Lane, et al.. (2024). Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurology. 82(1). 19–19. 15 indexed citations
3.
Boess, Frank, Marzia A. Scelsi, Timo Grimmer, et al.. (2024). At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. The Journal of Prevention of Alzheimer s Disease. 11(3). 537–548. 1 indexed citations
4.
Lansdall, Claire J., Edmond Teng, Paul Delmar, et al.. (2024). Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease. Alzheimer s & Dementia. 20(9). 5889–5900. 5 indexed citations
5.
6.
Gibbons, Elizabeth, et al.. (2023). Qualitative Exploration in Exit Interviews of Changes Observed in Clinical Trials for Individuals with Autism Spectrum Disorder Without Intellectual Disability. Patient Related Outcome Measures. Volume 14. 313–335. 3 indexed citations
7.
8.
9.
Zhu, Yajing, et al.. (2023). Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder. Neuropsychopharmacology. 48(8). 1201–1216. 9 indexed citations
10.
Bateman, Randall J., Jeffrey L. Cummings, Scott Schobel, et al.. (2022). Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimer s Research & Therapy. 14(1). 178–178. 70 indexed citations
11.
Jacob, Suma, Evdokia Anagnostou, Eric Hollander, et al.. (2022). Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Molecular Autism. 13(1). 25–25. 12 indexed citations
12.
Hollander, Eric, Suma Jacob, Roger J. Jou, et al.. (2022). Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder. JAMA Psychiatry. 79(8). 760–760. 29 indexed citations
13.
Bittner, T., Thomas Duning, Christina Rabe, et al.. (2020). P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results. Clinical Neurophysiology. 131(4). e194–e195. 4 indexed citations
14.
Gallagher, Robyn, et al.. (2018). Perspectives of cardiac rehabilitation staff on strategies used to assess, monitor and review – a descriptive qualitative study. Heart & Lung. 47(5). 471–476. 4 indexed citations
15.
Squassante, Lisa, Federico Bolognani, Janice Smith, et al.. (2018). 5.13 Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (Vanilla). Journal of the American Academy of Child & Adolescent Psychiatry. 57(10). S231–S231. 4 indexed citations
16.
Willgoss, Tom, Lisa Squassante, Kevin Sanders, et al.. (2018). 5.14 Psychometric Properties of a Novel Vineland-II 2-Domain Composite Score to Assess Social Communication and Social Interaction in ASD. Journal of the American Academy of Child & Adolescent Psychiatry. 57(10). S231–S232. 1 indexed citations
17.
Rolley, John, Janice Smith, Michelle DiGiacomo, Yenna Salamonson, & Patricia M. Davidson. (2010). The caregiving role following percutaneous coronary intervention. Journal of Clinical Nursing. 20(1-2). 227–235. 11 indexed citations
18.
Davidson, Patricia M., Michelle DiGiacomo, Penelope Abbott, et al.. (2008). A partnership model in the development and implementation of a collaborative, cardiovascular education program for Aboriginal Health Workers. Australian Health Review. 32(1). 139–146. 16 indexed citations
19.
Nardi, Deena, et al.. (2005). Community Need for University-Based Mental Health Services: Identifying the Top 5. Journal of Psychosocial Nursing and Mental Health Services. 43(11). 38–45. 3 indexed citations
20.
Smith, Janice, et al.. (2001). School Choice 2001: What's Happening in the States.. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zorana Pavlović Breakdown of academic impact, for papers by Martin Víta Breakdown of academic impact, for papers by Nicole Batsch Breakdown of academic impact, for papers by Louise Taylor Breakdown of academic impact, for papers by Konstantinos Bonotis Breakdown of academic impact, for papers by Chieh-Liang Huang Breakdown of academic impact, for papers by Kevin Butler Breakdown of academic impact, for papers by Zeeshan Mansuri Breakdown of academic impact, for papers by Morgan Green Breakdown of academic impact, for papers by Susan Worley
Rankless by CCL
2026